In this guide
What is resistant starch?
Resistant starch is starch and starch-degradation material that escapes digestion in the small intestine. The fraction reaching the colon can be fermented by microbes, so it overlaps functionally with dietary fibre. Resistance can come from physical enclosure in a food, an ungelatinized granular structure, retrogradation after cooking and cooling, chemical modification or a starch-lipid complex. [1], [2]
The common numbered forms are descriptive categories. RS1 is physically inaccessible within intact structures; RS2 is granular starch in sources such as raw potato, green banana or high-amylose maize; RS3 is retrograded starch formed after gelatinized starch cools; RS4 is chemically modified; and RS5 is complexed with lipid. A trial of HAM-RS2 does not prove that cooked-and-cooled rice, raw potato starch and an RS4 bakery ingredient have the same dose or effect. [2]
Mass and identity
A powder amount is not automatically its RS amount
Do not copy the active fraction onto every scoop or other product.
Typical Resistant Starch Protocols
| Study and population | Exact product | Amount each administration | Frequency | Daily total and duration | Main interpretation |
|---|---|---|---|---|---|
| Bodinham 2014 · 17 adults with well-controlled type 2 diabetes | Hi-Maize 260, 60% HAM-RS2 | 33.5 g product per sachet; 20 g RS2 | Twice daily | 67 g product providing 40 g RS2/day for 12 weeks | Meal glucose improved; HbA1c and clamp insulin sensitivity did not |
| Peterson 2018 · 68 adults with prediabetes; 59 analyzed | Hi-Maize 260 HAM-RS2 in yogurt and packets | Not reported | Daily schedule not reported | 45 g RS2/day for 12 weeks | No meaningful glycemic or broad cardiometabolic improvement |
| Venkataraman 2016 · 20 healthy young adults | Raw unmodified potato starch, about 50% RS2 | 24 g product; about 12 g RS2 after ramp | Twice daily after a 3-day ramp | 48 g product providing about 24 g RS2/day for 7 maintenance days | Fecal butyrate response varied substantially |
| Luk-In 2024 · 98 Thai adults with chronic constipation; 87 completed | Haruna Plus mixed-source RS3 | 9 g | Once daily | 9 g/day for 12 weeks | No significant between-group difference in stool frequency, consistency or constipation score |
The Bodinham paper states that participants used two daily sachets, so its per-administration product and RS2 amounts can be calculated directly from that explicit schedule. Peterson reports 45 g/day delivered through yogurts and packets but does not disclose a defensible equal split; “not reported” is more accurate than dividing it. Venkataraman ramped product mass from 12 g on day one to 24 g on day two and 48 g on day three before seven maintenance days. [4], [5], [6]
- Product versus active fraction
- A potato or maize starch powder can contain digestible starch as well as RS. Record both values when the source provides them.
- RS type
- RS2 and RS3 are created by different structures. A quantity from one cannot define the other.
- Comparator
- Bodinham and Peterson used rapidly digestible starch comparators; Luk-In used a soy-protein/isomalt placebo. Comparator effects can influence the difference.
What is resistant starch commonly used for?
Post-meal glucose and long-term glycemic control
Bodinham’s small crossover study found lower postprandial glucose after 12 weeks of HAM-RS2 and a larger post-meal GLP-1 excursion. Those signals did not extend to fasting glucose, insulin, HbA1c, hepatic insulin sensitivity or peripheral clamp insulin sensitivity. Fasting triglycerides and soleus intramuscular triglycerides were higher after HAM-RS2, an unfavorable signal with uncertain clinical meaning. [4]
Peterson’s larger parallel trial is the counterweight. Relative to amylopectin, 45 g/day HAM-RS2 reduced HbA1c by only 0.1 percentage point, which the authors called clinically insignificant, and did not improve insulin secretion, insulin sensitivity, disposition index, meal glucose or insulin areas, ectopic fat, energy expenditure or most cardiovascular measures. Heart rate and TNF-alpha fell, but baseline TNF-alpha was higher in the RS2 group. Ingredion supplied both products, and two authors reported prior company research funding or product gifts; sponsors had no role in the trial. [5]
Fermentation and butyrate
Venkataraman observed a cohort increase in fecal butyrate from 8 to 12 mmol/kg after raw potato starch, but response groups diverged. Eleven participants increased from about 9 to 15 mmol/kg, three started and remained high, and six remained at or below 8 mmol/kg. Changes in resistant-starch degraders helped explain some variation. Fecal butyrate is still an intermediate outcome influenced by production, absorption and transit; the study did not test symptom relief or disease prevention. [6]
Constipation
Luk-In’s mixed-source RS3 product produced favorable within-group changes and microbiome shifts. Yet placebo participants also improved, and direct between-group differences in stool frequency, Bristol stool score and modified constipation score were not significant. The reported 80% reaching at least four bowel movements per week describes the active group, not a significant placebo-adjusted effect. The formulation was an autoclaved-and-cooled blend of ginkgo nut, spinach, corn and brown rice, so it cannot validate home-cooled starch at the same weight. [7]
Twenty-person mechanistic study
The same potato starch produced three butyrate patterns
These are fecal biomarker clusters, not symptom responder rates.
How do you read the form and label?
Look for the starch source, RS type, product grams per serving, measured resistant-starch grams and testing method. “High amylose” does not tell you the exact resistant fraction after processing. Raw potato starch loses much of its granular resistance when heated with moisture; a cooked finished food cannot inherit the raw-powder value. RS3 depends on gelatinization, cooling, storage and reheating conditions. [2], [8]
Cooking and cooling can increase retrograded starch, but the amount is food- and process-specific. It does not erase digestible carbohydrate, energy or glycemic impact. Home preparation without laboratory measurement should be described as a processing strategy, not a known gram dose.
In the United States, FDA guidance recognizes certain resistant starches for dietary-fibre declaration based on evidence for physiological effects. That is a labelling determination, not approval to treat diabetes or constipation. Canada treats naturally occurring RS1 and conventional RS3 as dietary fibre and evaluates some manufactured RS sources within its novel-fibre evidence framework. [3], [8]
How should resistant starch be stored?
Keep powders sealed, dry and away from humidity. Follow product directions and avoid heating raw RS2 products when the intended property depends on intact granules. Prepared starchy foods require ordinary food-safety refrigeration and reheating practices; creating RS3 does not make cooked rice or potatoes safe to leave at room temperature. A multi-ingredient fibre blend may have different storage requirements from plain starch.
What does the human evidence show?

| Question | Best direct evidence here | Answer | Main limit |
|---|---|---|---|
| Does HAM-RS2 improve long-term diabetes control? | 17-person crossover trial | No HbA1c or clamp-sensitivity benefit | Small sample; post-meal signal only |
| Does 45 g/day RS2 improve prediabetes broadly? | 68-person parallel RCT | No meaningful glycemic or broad cardiometabolic benefit | 59 analyzed; supplied product and prior company ties |
| Does potato RS2 raise butyrate in everyone? | 20-person mechanistic study | No; 6 stayed low | Short uncontrolled exposure; fecal biomarker |
| Does 9 g/day mixed RS3 outperform placebo for constipation? | 98-person randomized trial | No significant difference on main stool indexes | Within-group improvement and favorable trends |
These studies use different populations, products and outcomes. A positive meal test, a lower inflammatory marker, more fecal butyrate and easier stooling are not interchangeable endpoints. The most useful conclusion is that resistant starch can alter physiology, while clinically important effects remain product- and context-dependent. [4], [5], [6], [7]
What are the risks and interactions?
Gas, bloating, cramps, altered stool frequency and loose stool are expected fermentation-related effects. Rapid increases can be difficult to tolerate. A new symptom is not proof of beneficial “feeding” or detoxification. Severe or persistent abdominal pain, vomiting, marked distension, blood in stool, fever, dehydration or signs of obstruction require assessment.
Resistant starch can change post-meal glucose in some settings. People using insulin or glucose-lowering medicine should avoid assuming a predictable effect from one product or cooled food and should discuss meaningful dietary changes with their clinician. Suspected obstruction, severe motility disorders, active inflammatory disease or recent gastrointestinal surgery also call for clinical review. Fibre can alter transit; follow medicine-specific instructions rather than applying the two-hour spacing used in one RS3 study to all medicines.
What is the legal and regulatory status?
In the United States, resistant-starch products may be conventional foods or dietary supplements. FDA dietary-fibre recognition applies to defined ingredients and physiological evidence; it is not disease-treatment approval. In Canada, conventional RS1 and RS3 and accepted manufactured fibres fall under product- and evidence-specific food rules. A powder sold as a natural health product can follow a different classification pathway. [3], [8]
What happens when you stop?
Resistant starch does not cause drug-like withdrawal. Fermentation, fecal butyrate and stool pattern may return toward baseline when the substrate is removed. A meal response may change immediately with the food matrix, while microbial measurements can lag. No validated taper exists; persistent symptoms after stopping suggest another dietary or medical factor.
What should you monitor?
Record product grams, stated resistant-starch grams, type, preparation and meal context. Choose one primary outcome: stool frequency, Bristol stool form, bloating score or clinician-guided glucose measure. Note a baseline and concurrent fibre, probiotic, laxative and medication changes. Review at the study-relevant window, from days for fermentation to 12 weeks for the metabolic trials, without overlooking earlier intolerance.
What does community experience add?
Public reports can surface gas, preparation confusion and the difference between powder scoops and cooled foods. They rarely measure the resistant fraction or control diet, medicines and baseline microbiome. No systematic current community sample was assembled, so no consensus percentage, titration schedule or responder rate is reported.
How do resistant-starch forms compare?
| Option | Identity | Evidence boundary |
|---|---|---|
| HAM-RS2 | High-amylose maize product | Metabolic trials at 40–45 g RS2/day; mixed and mostly negative long-term outcomes |
| Raw potato RS2 | Ungelatinized potato granules | Short microbiome study used 48 g product, about 24 g RS2/day |
| Mixed-source RS3 | Autoclaved-and-cooled commercial blend | One 9 g/day constipation trial without significant main between-group differences |
| Cooked-and-cooled food | Food-specific retrograded starch | Actual RS depends on food, processing, storage and reheating |
| Psyllium | Viscous gel-forming fibre | Different mechanism, medication-spacing concerns and bowel evidence |
Common questions
Is resistant starch a dietary fibre?
It functions as fibre because it escapes small-intestinal digestion. Labelling treatment still depends on jurisdiction, type and evidence. [3], [8]
Is raw potato starch all resistant starch?
No. Venkataraman’s product was about 50% RS2 by weight. Product mass was roughly twice the estimated RS amount. [6]
Does cooking and cooling increase resistant starch?
It can create RS3 through retrogradation, but the amount depends on the food and process. It does not remove all digestible starch.
Does resistant starch lower blood glucose?
Bodinham found a post-meal signal without better HbA1c or clamp sensitivity. Peterson found no meaningful broad glycemic improvement. [4], [5]
Does it help constipation?
The 2024 RS3 trial improved from baseline, but direct comparisons with placebo on the main stool indexes were not significant. [7]
Does everyone produce more butyrate?
No. Six of 20 participants in one short potato-starch study remained in the low-response group. [6]
Is more resistant starch better?
No dose-response across forms is established. Larger fermentable loads can worsen tolerance, and trial quantities cannot be transferred across products.
Glossary
Plain explanations of resistant-starch and outcome terms.
- RS2
- Resistant starch protected by its native granular structure, as in raw potato or high-amylose maize.
- RS3
- Retrograded starch formed when gelatinized starch molecules reassociate during cooling.
- Gelatinization
- Heat-and-moisture disruption of starch granules that usually increases digestibility.
- Retrogradation
- Reassociation of cooked starch chains during cooling, which can increase digestion resistance.
- Butyrate
- A short-chain fatty acid made by microbial fermentation; fecal concentration reflects several processes.
- Euglycemic clamp
- A controlled research method for measuring insulin sensitivity.
How this guide was researched
Primary full reports supplied the exact product, resistant fraction, schedule, comparator and outcome boundaries for HAM-RS2, potato RS2 and mixed RS3. Negative glycemic results, higher triglyceride signals, Peterson’s participant flow and company relationships, Venkataraman’s low-response group and Luk-In’s nonsignificant between-group stool results remain explicit. Official US and Canadian documents supplied fibre-labelling distinctions. Community claims were not quantified.
Research record · checked October 9, 2026
Fresh reads: full primary reports for Bodinham 2014, Peterson 2018, Venkataraman 2016 and Luk-In 2024 were checked.
Protocol verification: product mass and estimated RS mass are separated; Peterson’s unreported administration split was not invented.
Negative evidence: null HbA1c and insulin-sensitivity findings, triglyceride signals, microbiome nonresponders and nonsignificant RS3 placebo comparisons remain visible.
Claim boundary: fecal butyrate, microbiome abundance and within-group stool changes were not promoted into clinical efficacy.
Explore the sources
Primary human studies, reviews and official fibre guidance supporting this guide.
Showing 8 sources
- 01
Resistant starch definition in Dietary Reference Intakes ↗
Reference definition
Class definition and digestion boundary.
- 02
Resistant starch: promise for improving human health. ↗
Scientific review
Types, processing and mechanistic context.
- 03
Scientific evidence on physiological effects of non-digestible carbohydrates ↗
Official evidence review
US dietary-fibre labelling context.
- 04
Efficacy of increased resistant starch consumption in human type 2 diabetes. ↗
Randomized crossover trial
Exact product fraction, meal signal, null outcomes and triglycerides.
- 05
Effect of 12 wk of resistant starch supplementation on cardiometabolic risk factors in adults with prediabetes: a randomized controlled trial. ↗
Randomized controlled trial
Participant flow, broad null outcomes and disclosures.
- 06
Variable human microbiome responses to resistant starch ↗
Human mechanistic study
Exact potato-starch schedule and heterogeneous butyrate response.
- 07
Impact of resistant starch type 3 on fecal microbiota and stool frequency in Thai adults with chronic constipation randomized clinical trial. ↗
Randomized controlled trial
Product-specific protocol and nonsignificant main between-group comparisons.
- 08
Policy for Labelling and Advertising of Dietary Fibre-Containing Food Products ↗
Official policy
Canadian RS types and novel-fibre evidence requirements.
No matching sources
Try a different term or show the full list.
Editorial note
This guide preserves exact product and active-fraction amounts, negative comparator findings, sponsor context and the distinction between biomarkers and clinical outcomes. It was authored in English for translation from the same evidence record.